Aerovate Therapeutics (AVTE) Q2 2024 earnings summary

Executive summary

• Announced negative Phase 2b results for AV-101 in PAH, halting all development and clinical trials for AV-101, the only product candidate in the pipeline.

• Initiated a comprehensive review of strategic alternatives, including potential acquisition, merger, business combination, liquidation, or other transactions, with Wedbush PacGrow as exclusive financial advisor.

• Implemented a workforce reduction plan, terminating 69% of employees by July 31, 2024, with estimated one-time severance costs of $5.6 million.

Financial highlights

• Net loss for Q2 2024 was $24.8 million, compared to $19.0 million in Q2 2023; net loss for the six months ended June 30, 2024 was $48.0 million, up from $35.5 million year-over-year.

• Operating expenses for Q2 2024 were $26.2 million, up from $20.3 million in Q2 2023, driven by increased R&D and G&A costs.

• Cash and cash equivalents plus short-term investments totaled $104.2 million as of June 30, 2024.

• Net cash used in operating activities for the first half of 2024 was $44.1 million, compared to $26.4 million in the prior year period.

• Raised $23.6 million in net proceeds from ATM equity sales in H1 2024; $6.0 million remains available under the program.

Outlook and guidance

• Does not intend to resume development of AV-101 or any other product candidates at this time.

• Existing cash and investments expected to fund operations for at least twelve months from the filing date while strategic alternatives are explored.

• Future capital requirements will depend on the outcome of the strategic review and any potential transaction.